[Basic and clinical strategy for the control of allergic disorders].
Taniguchi
Masaru
M
RIKEN Research Centerfor Allergy and Immunology.
D000917:Antibody Formation; D001500:BCG Vaccine; D005038:Ethylnitrosourea; D005799:Genes, Dominant; D005808:Genes, Recessive; D023281:Genomics; D016045:Human Genome Project; D006801:Humans; D006967:Hypersensitivity / Q000209:etiology* / Q000628:therapy*; D007113:Immunity, Innate; D007073:Immunoglobulin E; D008285:Major Histocompatibility Complex / Q000235:genetics / Q000276:immunology; D008407:Mast Cells / Q000276:immunology; D009154:Mutation; D011058:Pollen / Q000276:immunology; D040901:Proteomics; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D051193:Toll-Like Receptors / Q000276:immunology; D014612:Vaccines / Q000627:therapeutic use
D001500:BCG Vaccine; D051193:Toll-Like Receptors; D014612:Vaccines; D007073:Immunoglobulin E; D005038:Ethylnitrosourea